July 8, 2024 10:50 AM EDTUpdated 11:15 AM
R&D

Hill­e­Vax's stock tum­bles af­ter Phase 2b norovirus vac­cine fails in in­fants

Katherine Lewin

News Reporter

Take­da spin­out Hill­e­Vax’s stock $HLVX sunk over 85% on Mon­day morn­ing af­ter the com­pa­ny an­nounced its norovirus vac­cine can­di­date failed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times